Voyager COO granted RSUs and 210,000 stock options

Voyager Therapeutics COO & CBO Robin Swartz reported new equity awards in the company.

Rhea-AI Filing Summary

Voyager Therapeutics COO & CBO Robin Swartz reported new equity awards in the company. On February 6, 2026, Swartz was granted 45,000 shares of common stock for no cash consideration, issuable under restricted stock units awarded pursuant to the 2025 Stock Incentive Plan. Following this grant, Swartz beneficially owned 214,647 shares of common stock directly.

On the same date, Swartz received a stock option for 210,000 shares of common stock with an exercise price of $3.68 per share, expiring on February 6, 2036. The RSUs vest over three years in annual installments, and the option vests monthly over four years, in each case conditioned on continued service.

Insider Trade Summary

Grant/Award: 255,000 shares

Grant/Award 2 txns

Insider Swartz Robin

Role COO & CBO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	210,000	$0.00	$0.00
Grant/Award	Common Stock	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 210,000 contracts (Direct); Common Stock — 214,647 shares (Direct)

Footnotes (2)

1. F1. Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
2. F2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Voyager Therapeutics (VYGR) report for Robin Swartz?

Voyager Therapeutics reported that officer Robin Swartz received equity awards on February 6, 2026. These consisted of 45,000 RSU-based common shares at no cost and a stock option for 210,000 shares under the 2025 Stock Incentive Plan, both subject to vesting.

How many Voyager Therapeutics (VYGR) shares does Robin Swartz beneficially own after this Form 4?

After the reported grant, Robin Swartz beneficially owns 214,647 shares of Voyager Therapeutics common stock directly. This total reflects the addition of 45,000 shares issuable under newly awarded restricted stock units, subject to the specified vesting schedule and continued service.

What are the terms of Robin Swartz’s RSU award at Voyager Therapeutics (VYGR)?

Swartz received 45,000 restricted stock units (RSUs) on February 6, 2026. Each RSU converts into one common share upon vesting. The award vests over three years, with one-third vesting on the first anniversary and additional one-third portions vesting annually thereafter, conditioned on continued service.

What are the details of Robin Swartz’s stock option grant at Voyager Therapeutics (VYGR)?

Swartz received a stock option for 210,000 shares of Voyager Therapeutics common stock at an exercise price of $3.68 per share. The option was granted on February 6, 2026 and expires on February 6, 2036, vesting monthly over four years with continued service.

How does the stock option for Robin Swartz at Voyager Therapeutics (VYGR) vest?

The stock option vests over four years. Starting from the February 6, 2026 grant date, 1/48th of the underlying 210,000 shares vests on the one-month anniversary, with an additional 1/48th vesting at the end of each successive month, subject to continued service.

How do Robin Swartz’s RSUs at Voyager Therapeutics (VYGR) vest over time?

The 45,000 RSUs granted to Robin Swartz vest over three years. One-third of the underlying common shares vests on the first anniversary of the February 6, 2026 grant date, with the remaining shares vesting in equal one-third installments annually thereafter, conditioned on continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swartz Robin

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A		45,000(1)	A	$0.00	214,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.68	02/06/2026		A		210,000		(2)	02/06/2036	Common Stock	210,000	$0.00	210,000	D

Explanation of Responses:

1. Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Robin Swartz	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.